Effects of the PPAR𝛼 Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism

Table 1

Survival, body weights, average daily doses, and feed consumption in male core study Harlan Sprague Dawley rats, B6C3F1 mice, and Syrian hamsters following exposure to gemfibrozil in feed for 14 weeks^a.

Dose (ppm)	Survival^a	Initial Body Weight^b (g)	Final Body Weight^b (g)	Body Weight Change^b (g)	Final Body Weight (% Con)	Wk 1 Feed Consumption (g/animal/day)	Week 13 Feed Consumption (g/animal/day)	Average Daily Dose (mg/kg)
Rats
0	10/10	236±3	436±5	201±3	—	20.9	19.1	—
10	10/10	236±2	424±9	189±8	97	19.9	18.6	0.6
100	10/10	235±2	432±8	197±7	99	21.5	20.8	6
1000	10/10	237±3	410±16	173±14^∗	94	20.2	20.1	60
8000	10/10	231±3	350±9^∗∗	119±7^∗∗	80	13.0	19.3	510
16000	10/10	237±2	286±7^∗∗	49±6^∗∗	66	7.5	22.8	1300
Mice
0	10/10	22.1±0.1	33.7±0.6	11.6±0.5	—	5.3	6.4	—
10	10/10	22.1±0.2	35.5±0.8	13.4±0.6	105	6.0	5.4	1.9
100	10/10	22.1±0.3	35.1±0.7	13.0±0.7	104	5.8	5.5	19
1000	10/10	21.2±0.2	34.4±0.6	12.2±0.5	102	6.0	6.2	210
4000	10/10	21.5±0.2	32.0±0.3	10.5±0.3	95	5.8	7.4	920
8000	10/10	22.0±0.2	28.8±0.2^∗∗	6.7±0.3^∗∗	85	5.9	7.6	2100
Hamsters
0	10/10	78±1	115±2	37±2	—	8.8	7.3	—
100	10/10	79±2	125±4	46±4	108	8.0	7.4	7
1000	10/10	77±2	118±3	40±2	102	7.8	7.0	80
6000	10/10	76±2	120±4	44±4	104	7.9	6.8	480
12000	10/10	78±2	109±5	30±5	95	7.6	7.2	970
24000	10/10	79±2	99±4^∗∗	20±3^∗∗	86	9.7	6.3	2000

^∗Significantly different (𝑃≤.05) from the control group by Williams’ test; ^∗∗𝑃≤.01; ^aNumber of animals surviving at 3 months/number initially in group; ^bMean±standard error.